Impact of Coronary Sinus Reducer on Coronary Microcirculation in Refractory Angina [0.03%]
冠状窦闭塞器对难治性心绞痛患者冠脉微循环的影响
Szymon Włodarczak,Piotr Rola,Artur Jastrzębski et al.
Szymon Włodarczak et al.
Robert Sykes,Meriam El-Hirch,Simone Biscaglia et al.
Robert Sykes et al.
Balloon-Expandable Transcatheter Heart Valve Hemodynamic Parameters: Time to Reconsider What They Mean [0.03%]
可扩张经导管心脏瓣膜的血流动力学参数：是时候重新考虑其意义了
Masanori Yamamoto
Masanori Yamamoto
Impact of Aortic Annulus Size on Outcomes After Aortic Valve Replacement: The PARTNER 3 Trial [0.03%]
主动脉瓣置换术后主动脉瓣环大小对预后的影响：PARTNER 3试验
Mahesh V Madhavan,Michael J Mack,Philippe Pibarot et al.
Mahesh V Madhavan et al.
Background: There are limited studies comparing the impact of transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) by annular size. ...
Randomized Controlled Trial
JACC. Cardiovascular interventions. 2026 Jul 27;19(14):1944-1955. DOI:10.1016/j.jcin.2026.05.023 2026
Reducing the Risk of Thrombotic Complications Following Valve-in-Valve TAVR: What Evidence Do We Need? [0.03%]
降低经导管主动脉瓣植入术中瓣中瓣治疗的血栓并发症风险：我们需要哪些证据？
Matthew A Cavender,Spencer Ng
Matthew A Cavender
Trends and Outcomes of Antithrombotic Strategies for Valve-in-Valve TAVR: The STS/ACC TVT Registry [0.03%]
美国胸外科协会/美国心脏协会电视节注册中心瓣中瓣经导管主动脉瓣置换术抗凝策略及其结局和趋势分析
Hiroki A Ueyama,Patrick T Gleason,Sreekanth Vemulapalli et al.
Hiroki A Ueyama et al.
Background: The optimal antithrombotic strategy after valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) for degenerated aortic bioprostheses remains undetermined, and current practice patterns in the Unit...
The Missing Dimension of Risk: From High-Risk Patients to High-Risk Periods [0.03%]
缺失的风险维度：从高风险患者到高风险时期
Antonio Greco
Antonio Greco
Timing of Bleeding and Ischemic Events in High-Bleeding Risk Patients Treated With 1-Month DAPT [0.03%]
一个月DAPT治疗高出血风险患者的出血和缺血事件的时间分布
Guillaume Marquis-Gravel,Davide Cao,Dylan Taylor et al.
Guillaume Marquis-Gravel et al.
Background: Understanding the concomitant evolution of bleeding vs ischemic risk after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) treated with 1-month dual antiplatelet therapy (DAPT)...
Drug-Coated Balloons in CTO PCI: Stentless When Feasible, Stent-Sparing When Necessary [0.03%]
药物涂层球囊在CTO PCI中的应用：可行时无需支架，必要时减少支架使用
Niccolò Ciardetti,Alessio Mattesini
Niccolò Ciardetti
Drug-Coated Balloon-Based Angioplasty for Chronic Total Occlusions: The PICCOLETO X Study [0.03%]
药物涂层球囊治疗慢性完全闭塞病变：PICCOLETO X研究
Bernardo Cortese,Gabriele Gasparini,Ludovic Meunier et al.
Bernardo Cortese et al.
Background: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) often requires extensive metal implantation, which may impair vascular vasomotor function and increase the risk for late adverse events. D...
Observational Study
JACC. Cardiovascular interventions. 2026 Jul 27;19(14):1895-1905. DOI:10.1016/j.jcin.2026.05.009 2026